SCHEMBL167883

SCHEMBL167883

O=C(OCc1ccccc1)c1cc(Br)c(C(=O)N2CCCCC2)cc1OCc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.55
ALDH1A1 P00352 3/20 0.55
MAPT P10636 2/20 0.55
ATM Q13315 1/20 0.55
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
NPSR1 Q6W5P4 1/20 0.54
POLB P06746 2/20 0.49
TSHR P16473 1/20 0.49
NPC1 O15118 5/20 0.46
RAB9A P51151 5/20 0.46
CASP3 P42574 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46
LMNA P02545 2/20 0.45
APP P05067 2/20 0.45
SCN9A Q15858 1/20 0.44
NMT1 P30419 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL168475 0.89 HSD17B10 (0.53) HPGDALDH1A1MAPTMEN1KMT2A
SCHEMBL166024 0.84 SMN1; SMN2 (0.51) HPGDALDH1A1MAPTATMMEN1
SCHEMBL168977 0.82 ALDH1A1 (0.57) ALDH1A1MEN1KMT2APOLBTSHR
SCHEMBL31363007 0.80 ALDH1A1 (0.53) ALDH1A1KMT2ASMN1; SMN2POLBTSHR
SCHEMBL382869 0.80 ALDH1A1 (0.53) ALDH1A1KMT2ASMN1; SMN2POLBTSHR
SCHEMBL23809724 0.79 ALDH1A1 (0.62) ALDH1A1MEN1KMT2ASMN1; SMN2NPSR1
SCHEMBL167731 0.79 NPC1 (0.46) HPGDALDH1A1MAPTMEN1KMT2A
SCHEMBL165393 0.79 MEN1 (0.46) HPGDALDH1A1MAPTATMMEN1
SCHEMBL23796954 0.78 ALDH1A1 (0.66) ALDH1A1KMT2APOLBTSHRLMNA
SCHEMBL1658628 0.77 APP (0.54) HPGDMEN1KMT2ASMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9365551-B2 2-(benzyloxy) benzamides as LRRK2 kinase inhibitors GLAXO GROUP LIMITED (GB) 2016-06-14 US disclosed
EP-2611772-B1 2-(BENZYLOXY)BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2014-09-24 EP disclosed
US-20130225584-A1 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-08-29 US disclosed
EP-2611772-A1 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2013-07-10 EP disclosed
WO-2012028629-A1 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225584-A1 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS LRRK2, PARK7, BRSK2 HPGD 3234/4885ALDH1A1 3544/4885MAPT 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.